What is Claimed is:

1. A cancer chemotherapeutic agent comprising, in combination, a cholestanol derivative represented by formula (1):



(1)

(wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent.

2. A cancer chemotherapeutic agent according to claim 1, wherein, in formula (1), G is GlcNAc-Gal- or GlcNAc-.

3. A cancer chemotherapeutic agent according to claim 1 or 2, wherein the anti-cancer agent is one or more species selected from the group consisting of a taxane anti-cancer agent, a platinum complex anti-cancer agent, a pemetrexed compound, and fluorouracil.

4. A cancer chemotherapeutic agent according to claim 3, wherein the anti-cancer agent is one or more species selected from the group consisting of Paclitaxel, Docetaxcel, Alimta, 5-FU, Cisplatin, Oxaliplatin, Cyclophosphamide, and Irinotecan.

5. A cancer chemotherapeutic agent according to claim 1 or 2, wherein the anti-cancer agent is one or more species

selected from the group consisting of a taxane anti-cancer agent, a pemetrexed compound, and fluorouracil.

6. A cancer chemotherapeutic agent according to claim 5, wherein the anti-cancer agent is one or more species selected from the group consisting of Paclitaxel, Docetaxcel, Pemetrexed, 5-FU, Cyclophosphamide, and Irinotecan.

7. A cancer chemotherapeutic agent according to any of claims 1 to 6, which is a compounding agent.

8. A cancer chemotherapeutic agent according to any of claims 1 to 6, which is in the form of a kit including a drug containing a cholestanol derivative and a drug containing an anti-cancer agent.

9. A cancer chemotherapeutic agent according to claim 8, wherein the drug containing a cholestanol derivative is a liposomal formulation.

10. Use, in combination, of a cholestanol derivative represented by formula (1):



(1)

(wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof and an anti-cancer agent, for producing a cancer chemotherapeutic agent.

11. Use according to claim 10, wherein the anti-cancer agent is one or more species selected from the group consisting of a taxane anti-cancer agent, a pemetrexed compound, and fluorouracil.

12. Use according to claim 11, wherein the anti-cancer agent is one or more species selected from the group consisting of Paclitaxel, Docetaxcel, Pemetrexed, 5-FU, Cyclophosphamide, and Irinotecan.

13. A cancer chemotherapy, characterized by comprising administering, in combination, a cholestanol derivative represented by formula (1):



(1)

(wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof and an anti-cancer agent, to a patient in need thereof.

14. A cancer chemotherapy according to claim 13, wherein the cholestanol derivative or a cyclodextrin inclusion compound thereof and the anti-cancer agent are administered to a patient in need thereof simultaneously, or separately and intermittently.

Claims

1. A cancer chemotherapeutic agent comprising, in combination, a cholestanol derivative represented by formula (1):



(1)

(wherein G represents GlcNAc- or GlcNAc-Gal-) or a cyclodextrin inclusion compound thereof, and Irinotecan as an anti-cancer agent.

2. A cancer chemotherapeutic agent according to claim 1, which is a compounding agent.

3. A cancer chemotherapeutic agent according to claim 1, which is in the form of a kit including a drug containing a cholestanol derivative and a drug containing an anti-cancer agent.

4. A cancer chemotherapeutic agent according to any one of claims 1 to 3, wherein the drug containing a cholestanol derivative is a liposomal formulation.

5. Use, in combination, of a cholestanol derivative represented by formula (1):



(1)

(wherein G represents GlcNAc- or GlcNAc-Gal-) or a cyclodextrin inclusion compound thereof and Irinotecan as an anti-cancer agent, for producing a cancer chemotherapeutic agent.